Sarepta Therapeutics, Inc. (SRPT) Guidance & Earnings Results
On 2026-08-05 Sarepta Therapeutics, Inc. mixed guidance: "FY26 total net product revenue narrowed to $1.2-$1.3B from $1.2-$1.4B; non-GAAP R&D and SG&A narrowed to $800-$850M from…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SRPTSarepta Therapeutics, Inc.Follow SRPT — free
—
Price chart with a free account
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Mixed | FY26 total net product revenue narrowed to $1.2-$1.3B from $1.2-$1.4B; non-GAAP R&D and SG&A narrowed to $800-$850M from $800-$900M · full year |
| 6 May 26 | Reaffirmed | Total net product revenues of $1.2 - $1.4 billion; combined non-GAAP R&D and SG&A expenses of $800.0 - $900.0 million. · full year |
| 25 Feb 26 | Reaffirmed | Anticipate remaining profitable and cash-flow positive in 2026 · full year |
| 12 Jan 26 | Reaffirmed | ELEVIDYS sales floor of $500M reaffirmed; no detailed guidance. · full year |
Sarepta Therapeutics, Inc. — questions
- What guidance did Sarepta Therapeutics, Inc. give?
- On 2026-08-05: "FY26 total net product revenue narrowed to $1.2-$1.3B from $1.2-$1.4B; non-GAAP R&D and SG&A narrowed to $800-$850M from $800-$900M"
- When does Sarepta Therapeutics, Inc. report earnings?
- Sarepta Therapeutics, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Sarepta Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.